Today, AMR is one of the world’s greatest health threats, causing over 1 million deaths each year, and that number is growing. If left unabated, the effects of AMR could be worse than COVID-19. Future projections suggest that AMR could result in millions of deaths and trillions of dollars in lost global production. BD is committed to combatting antimicrobial resistant (AMR).
Through this session, BD will provide the latest information on the treatment and diagnosis of multi-drug resistant GNB.
BD is a leading global medical technology company that develops, manufactures, sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
The BD Phoenix™ Automated Microbiology System is intended for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically significant bacteria. The BD Phoenix system provides rapid results for most aerobic and facultative anaerobic gram-positive bacteria as well as most aerobic and facultative anaerobic gram-negative bacteria of human origin.
Building on BD's excellence, experience, and expertise, the BD FACSLyric™ Flow Cytometry System is a tool for clinical cell analysis that improves the way flow cytometry is performed in the laboratory. As an essential tool for accurate and efficient immunofluorescence analysis, clinician can obtain fast, accurate results and support decision-making for patient care.